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European Journal of Cardio-thoracic Surgery 40 (2011) 840—847AbstractObjective: This study aimed to determine the acute and chronic performance of a new system designed to conduct beating-heart implantation
and off-pump adjustment of neochordal length.Methods: In 14 adult sheep (group A) selected to undergo beating-heart cardiopulmonary bypass,
the left atrium was opened through a left thoracotomy. Two or more primary chordae in the A2 region were severed to produce a model of a flail
leaflet. A chordal adjustment mechanism (V-Chordal, Valtech Cardio Ltd., Or-Yehuda, Israel) was affixed to the head of the papillary muscle. The
system includes two adjustable neochordae. The distal end of the neochordaewas sutured to the flail segmentwithout estimating the appropriate
length. The neochordal length was adjusted off-pump under real-time echo-guidance. The adjustment tool was removed and the atriotomy was
closedwith a purse-string suture. Control animals (group B, n = 4) were implantedwith the conventional neochordae. Animals in both groupswere
sacrificed 3 months after the procedure. Results: In both groups, prior to repair, mitral regurgitation (MR) was severe in all animals. In group A,
following adjustment of neochordae, MR was absent in all animals, with the exception of two animals that had residual 2+ MR irresponsive to
neochordae adjustments. In group B, MR was 2+ in two of the four animals following repair. At 3 months, mitral competence was stable in all
animals. At necropsy, normal healing of the papillary head and leaflet was observed in both the groups. Conclusions: The V-Chordal system
simplifies the process of neochordal implantation and precise off-pump adjustment of the neochordal length to correct MR occurring due to a flail
leaflet. This technology may improve the technical feasibility for adoption of chordal repair during open or minimally invasive surgical
procedures.
# 2011 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
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The implantation of neochordae is a proven surgical
technique for the correction of mitral regurgitation (MR)
occurring due to prolapse and flail leaflet [1—4]. Although
neochordae implantation has been mainly adopted to treat
anterior leaflet prolapse, in recent times, it has been used as
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doi:10.1016/j.ejcts.2011.01.021leaflet [3], with comparable results [2]. Compared with
resection, the implantation of neochordae restores mitral
anatomy while preserving leaflet tissue. The main advantage
of this technique is attributed to its ability for creation of a
larger surface for coaptation, which favors better and more
durable hemodynamics [5].
Although its intrinsic superiority, compared with other
techniques, has been recognized for several years, neochor-
dae implantation has only been adopted slowly, primarily due
to the challenge of determining the optimal neochordal
length during cardioplegic arrest. In this study, a device
designed to allow beating-heart adjustment of neochordal
length after implantation was investigated. By using this
feature, the surgeon could correct neochordal length under
physiologic conditions to improve prolapse correction.
This article reports acute and chronic results from a
comparative study designed to evaluate the safety and
performance of a device-based, adjustable neochordalurgery. Published by Elsevier B.V. All rights reserved.
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Ltd., Or-Yehuda, Israel), versus conventional neochordae
implantation in an animal model of MR secondary to flail
leaflet.2. Methods
2.1. The flail model
Eighteen adult sheep underwent general anesthesia with a
standardized protocol. Anesthesia was induced and main-
tained by the administration of isoflurane (2%). A minimally
invasive left thoracotomy (muscle-sparing approach) was
performed on all animals.
Baseline echocardiography was performed using epicar-
dial probes. The probe was positioned at the atrioventricular
groove, in the region of the anterolateral commissure. Short-
axis views of the annulus were taken and measurements
recorded. Intercommissural (CC) and septolateral (SS)
dimensions were recorded in each animal during both systole
and diastole. In addition, the annular area in diastole and the
degree of baseline MR was determined by Color Doppler. The
degree of MR was assessed by a multiparametric method,
using the jet area in the left atrium, the width of the vena
contracta, and the duration of MR in the cardiac cycle with
Color-Doppler M-mode [6]. The baseline data for both groups
are reported in Table 1.
Following full heparinization, the descending aorta
(arterial line) and pulmonary artery (venous line) were
cannulated and cardiopulmonary bypass was initiated.
Vacuum-assisted venous return was used in most of the
cases. With the heart decompressed, the left atrium was
opened longitudinally 2 cm above the atrioventricular groove
without aortic cross-clamping. A 4/0 polypropylene suture
was then positioned in the middle of the anterior leaflet, at
the junction of the chordae originating from the posterior
and anterior leaflets to improve exposure of the papillary
muscle and to support the leaflet during implantation of the
neochordae. To create a consistent model of flail anterior
leaflet, a variable number (between two and four) of chordae
originating from the anterior (two animals, both in the
experimental group) or posterior (16 animals) papillary
muscle and attached to the A2 were cut in order to create an
unsupported segment of leaflet extending for approximately
1 cm along the free edge. The 4/0 polypropylene suture was
left in place to support the flail segment until reconstruction
with either the experimental device or the conventional
polytetrafluoroethylene (PTFE) suture was completed, and
was removed thereafter.Table 1. Baseline anatomical variables. Baseline dimensions of the mitral valve in
deviation (range in brackets).
Overall
n
AP diastolic diameter (mm) 2.4  0.2 (2.0—2.7)
AP systolic diameter (mm) 1.9  0.2 (1.7—2.2)
CC diastolic diameter (mm) 3.5  0.3 (3.0—4.1)
CC systolic diameter (mm) 2.8  0.2 (2.4—3.2)
Area (cm2) 6.5  0.4 (5.9—7.2)
MR baseline (0—4) 0.4  0.5 (0—1)2.2. The control group
In four animals, following chordal cutting, a 5/0 PTFE
suture was used to perform a conventional neochordal
implant. The neochordal technique used has been consistent,
and is described in the following. A double-ended PTFE suture
was positioned at the tip of the posterior papillary muscle in a
figure-of-eight manner and tied. The two ends of the suture
were then attached to the free edge of the flail segment, in a
locking manner to reduce the slippery tendency of the PTFE.
Neochordal length was assessed on the beating heart by
comparison of coaptation height of the posterior leaflet.
Following determination of neochordal length, the PTFE
suture was tied on the ventricular surface of the leaflets, the
4/0 polypropylene stay suture was removed, and the left
atrium was closed with 4/0 polypropylene. A left vent was
left in place for de-airing. Weaning from cardiopulmonary
bypass was performed easily. Echo measurements of mitral
valve competence were repeated (Fig. 1A). Protamine was
administered. Cardiopulmonary bypass cannulae were
removed, and the chest was closed in the usual manner.
2.3. The experimental group
Fourteen animals underwent implantation of the adjus-
table neochordae device following severing of native
chordae.
The Valtech V-Chordal Adjustable System consists of two
primary elements (Fig. 2): the neochordal implant and the
delivery system. The neochordal implant has a metallic
helical fixation element, for sutureless implantation of the
device in the papillary muscle. The implant core is a Dacron-
covered, micro-locking, adjustment spool preloaded with a
double-ended 3/0 polyester-braided suture coated with PTFE
and connected to tapered needles. The delivery system
comprises a flexible shaft that engages the spool mechanism
during fixation and adjustment of neochordal length, and an
adjusting handle. The handle has two knobs, one to activate
the sutureless fixation on the papillary muscle and another to
perform high-resolution regulation of neochordae length in
the beating heart under physiologic loading conditions prior
to surgical closure (Fig. 2). Following implantation, neo-
chordal length can be increased or decreased (within a range
of 3 cm), and any adjustment is fully reversible. The flexible
shaft is detached from the neochordal implant at the end of
the adjustment.
Following chordal cutting, the V-Chordal Delivery System
was inserted across the mitral valve. The head of the
posterior papillary muscle was stabilized. The V-Chordal
device was then implanted in the fibrous tissue at the tip ofthe experimental and the control groups are reported as means  standard
V-Chordal group Control group
14 4
2.4  0.2 (2.0—2.7) 2.4  0.2 (2.1—2.6)
1.9  0.1 (1.7—2.2) 2.0  0.2 (1.7—2.2)
3.5  0.3 (3.1—4.1) 3.5  0.3 (3.0—3.8)
2.8  0.2 (2.4—3.2) 2.9  0.3 (2.4—3.2)
6.5  0.3 (5.9—7.1) 6.7  0.5 (6.1—7.2)
0.4  0.5 (0—1) 0.5  0.6 (0—1)
F. Maisano et al. / European Journal of Cardio-thoracic Surgery 40 (2011) 840—847842
[()TD$FIG]
Fig. 1. Echo-Doppler assessment of MR. Top: Control group, four animals.
Assessments were performed at baseline, after neochordal implant, following
discontinuation of cardiopulmonary bypass and at 90 days, prior to sacrifice.
The numbers in the boxes indicate how many animals presented with a certain
degree of MR at the selected time. Connecting lines show variations of MR
degree at each time point. Below are reported average MR degrees at the three
time points, with P-value of the statistical differences. Bottom: V-Chordal
group, 14 animals. Assessment was performed, with the addition of assessment
just following chordal cutting and V-Chordal reimplantation before adjust-
ment. The interpretation of data as above.
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Fig. 2. V-Chordal concept the V-Chordal system is composed of a neochordae
implant device (with a self-fixating helical element and a micro-locking spool)
and of a delivery system (adjusting handle and cable). A surgical view of the
adjusting handle shows the location of the fixation and of the adjustment knob.the papillary muscle using the helical fixation element
(Fig. 3A). Fixation was accomplished by slowly rotating (four
clockwise turns) the fixation knob on the adjustment handle
(Fig. 2). Appropriate engagement of the papillary muscle was
verified by application of gentle traction. Then, surgical
sutures, connected to the implanted device, were detached
from the shaft of the delivery system and sutured to the edge
of the mitral leaflet using the attached needles (Fig. 3B). No
assessment of neochordal length was conducted at this time,
and neochordae were tied longer than required to demon-
strate prolapse and to test the efficacy of the adjustment
system (Fig. 3C). The atrium was then closed with a running
stitch, with the shaft of the adjustment handle across the
atriotomy line (Fig. 3D); the animals were then weaned from
cardiopulmonary bypass. Thereafter, epicardial Doppler
echocardiography was performed to determine the degree
of MR due to prolapse. The implanted neochordal length wasadjusted by rotating the control knob on the adjustment
handle under real-time echocardiographic guidance until the
desired reduction of MR was achieved (Fig. 4). After releasing
the neochordae implant, the flexible delivery-system shaft
was withdrawn from the atrium. A final Doppler echocardio-
graphy was performed to determine the degree of MR at the
end of the adjustment and following the removal of the
delivery system. The chest was then closed in the standard
manner.
Animals were prepared for long-term survival, antibiotics
were administered, and animals recovered while under
observation. Animals in the chronic group were housed and
fed for 90 days prior to sacrifice. In the week prior to
sacrifice, all animals underwent transthoracic echocardio-
graphy. Gross anatomical and histopathological examinations
of the tip of the papillary muscle were performed in all
animals. For histopathological examination, tissue samples
were stained with standard hematoxylin and eosin stains.
2.4. Statistical methods
All data were collected in an electronic case report form
and assimilated prior to analysis. Statistical analysis was
conducted using the JMP version 5.1.1 software (SAS institute
Inc, Cary, NC, USA). Continuous variables are presented as
mean  SD. Univariate comparisons have been performed
using the Wilcoxon’s signed rank test for paired data. The
level of significance was set at P < 0.05. No comparisons
between experimental and control groups were undertaken
due to the disparity in group sizes.3. Results
Baseline echocardiographic findings were equal in both
groups (Table 1).
All animals underwent weaning from cardiopulmonary
bypass uneventfully and survived surgery. Anterior leaflet
flail lesions were effectively created in all animals by cutting
between two and four primary chordae in the A2 region.
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Fig. 3. Intraoperative view of the implant of the V-Chordal system. A: The V-Chordal device is implanted with a sutureless procedure in the tip of the papillary muscle
using the self-fixating helical element, activated by the handle. Note the 4-0 polypropylene stay suture in themiddle of the anterior leaflet. B: The 3-0 braided sutures
are positioned in the free edge of the anterior leaflet. At this time, the connecting cable is left aside, lying on the posterior commissure while the sutures are
implanted on the leaflet. C: Neochordae suture view prior to atrial closure. The connecting cable is still attached to the neochordae implant and is left across the
mitral coaptation line and across the atriotomy until beating-heart adjustment is done. D: The left atrium has been closed. The sutures are kept tight with a
tourniquet (blue tube) around the connecting cable (transparent tube). Epicardial echo probe is now positioned in the atrioventricular groove to guide adjustment.
(For interpretation of the references to color in this figure legend, the reader is referred to the web version of the article.)Following discontinuation of cardiopulmonary bypass, the
flail leaflet was apparent in animals that underwent V-
Chordal system implant, and was evident as a severe grade of
eccentric MR (Fig. 4A). Guided by echocardiographic
monitoring, flail lesions were corrected in all cases by using
either anatomical landmarks or the degree of MR for real-
time guidance. In certain cases, residual MR was nonrespon-
sive to adjustments. In such cases, the MR jet was centrally
directed, and there was evidence of the normal height of
coaptation of the treated leaflet. In such circumstances, the
neochordal length was determined solely on the basis of the
anatomical effect, and disregarding the Doppler findings. In
cases, the delivery system was easily disconnected from the
implant, with no bleeding from the atriotomy line and no
damage to the surrounding tissue. During final echocardio-
graphic measurements, all animals, with the exception of
two, showed no, or a trivial amount of, MR without any
evidence of residual flail lesions (Fig. 1B); in two animals(14%), there was persistent MR grade 2+/4+ with a non-
eccentric jet. The neochordae were visible on echo, as was
the implant position at the tip of the posteromedial papillary
muscle. It is notable that, inmost cases, the connecting cable
induced a minimal degree of MR due to the interference with
leaflets, but this did not impede assessment of neochordal
length.
In the control group, two animals showed residual MR of
grade 2+/4+, with non-eccentric jets (Fig. 1A).
All animals survived following the acute experiment and
up to the predefined time of sacrifice at 90 days. Prior to
sacrifice, at transthoracic Doppler echocardiography, mitral
competence was stable, and there were no significant
differences in degrees of MR in both groups (Fig. 1A and
B). At the post-mortem gross examination, the implant and
the neochordae were completely healed and there was
evidence of tissue ingrowth, with no gaps (Figs. 5 and 6). No
tissue tears were found adjacent to the neochordal implant
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Fig. 4. Echo-guided adjustment. Figures A—D show progressive reduction of systolic jet as the neochordae length is optimized under beating-heart conditions.on the free edge of leaflets. Papillary muscles exhibited
fibrous healing that was confined to the area of the implant
and there was no evidence of damage to the surrounding
tissue (Fig. 6). Histopathological examination revealed good
tissue ingrowths within the helical fixation element, and no
[()TD$FIG]
Fig. 5. Gross anatomy at post-mortem examination in a chronic animal
demonstrates normal healing of both the neochordae implant (arrow) and
of the neochordae sutures.sign of adverse cellular reaction to the implant. In addition,
gross pathology and histopathology findings in the control
group were normal.4. Discussion
The V-Chordal system enabled neochordal implantation
and precise off-pump adjustment of the neochordal length to
correct MR due to flail leaflet. Compared with conventional
neochordal implantation, the new system investigated in the
present study proved to be of similar safety and efficacy,
while minimizing the risk of inaccurate length determination,
and simplifying the implantation technique.
The device is implantable on the tip of the papillary
muscle with a sutureless semi-automated method. The
simplified method of fixation was effective and durable in
a beating, open, heart model, and it is expected to be equally
valuable under cardioplegic heart conditions. Neochordal
length is precisely regulated with high-resolution adjustment
on the beating heart, under echocardiographic guidance, to
safely and effectively optimize functional performance of
the mitral valve.
The implantation of neochordae is a well-established
method to treat leaflet prolapse and flail [1,7]. The
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Fig. 6. Gross anatomy at post-mortem examination in a chronic animal demonstrates the tip of papillary muscle in a V-Chordal (A) and a control (B) animal. Note the
absence of fibrosis in the surrounding tissue in picture A demonstrating minimal invasiveness of the device.implantation of artificial chordae is intrinsically more
physiologic than the method of leaflet resection [5], and it
has been associated with a larger orifice area following
repair, as compared with leaflet resection [2]. Further, the
preservation of leaflets is possibly associated with a wider
surface of coaptation [3], implying a potential for longer
durability of the repair and implant [8]. Although the
potential benefits of neochordae implantation are recog-
nized, the application of the procedure is limited by the
difficulty involved in determining appropriate length of
artificial PTFE sutures during cardioplegia. Several techni-
ques have been reported to accurately estimate the length of
the neochordae that are created during surgery, with sutures
anchored in the head of the papillary muscle [9]. The most
frequently used technique involves the adjustment of
chordal length during hydraulic testing of the static heart
(on cardiopulmonary bypass). This method is usually
effective; however, it can be unreliable, particularly in
cases of difficult exposure. In addition, the need for repeated
injections in the left ventricular cavity could increase the risk
of air embolization into the coronary circulation.
Other maneuvers include the estimation of the length of
healthy chordate adjacent to the affected chordae, and the
use of the annular-to-papillary-muscle distance [10]. In
addition, there are devices to guide chordal implantation by
adjusting the length using the annuloplasty level as a
reference [11].
In addition to the above-mentioned methods, the loop
technique has been developed to standardize and facilitate
minimally invasive implantation of neochordae: this method
comprises the implant of a pre-sized group of looped sutures.In this method, the length is determined on either anatomical
or echocardiographic measurements [12]. The loops are
connected to the tip of papillary muscles and to free edges of
leaflets with polypropylene sutures, thus minimizing the risk
of overreduction of length during knot tying. This feature,
associated with the avoidance of intraoperative sizing, is
particularly desirable in the setting of minimally invasive
repair.
All the above-mentioned techniques for sizing of chordal
length are limited by the static determination of chordal
length during cardioplegic arrest. The post-implant control of
appropriate sizing is based on ventricular saline injection and
direct view of valve competence. Although this method is
often valuable, it is not always reliable, because it assesses
coaptation during non-physiologic conditions [13]. In an
effort for a more physiologic control of chordal length,
transapical off-pump implantation of neochordae has been
proposed as an alternative to conventional techniques
[14,15]. This technology is promising; nonetheless, its
clinical role has yet to be determined in clinical trials to
elucidate the durability of implants. In addition, its
applicability could be influenced by leaflet anatomy,
presence of leaflet segments requiring resections, or the
need for an annuloplasty.
To date, the V-Chordal system is the only device designed
for sutureless implantation of neochordae under cardioplegic
arrest that allows subsequent adjustment on the beating
heart. The device has a flexible shaft that allows remote
activation of a fixation element in the head of the papillary
muscle. The use of this mode of fixation simplifies the process
by reducing suture handling, and it is possibly safer because
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with the native chordae than a conventional figure-of-eight
suture. Papillary muscle fixation has been performed with no
complications in the experimental series, although this step
has been performed under beating-heart conditions. Gross
anatomical examination following sacrifice at 3 months
showed complete healing of the neochordal implant, which
was covered by endothelium, and the absence of lesions in
the surrounding tissue (no chordal abrasions and no ischemic
lesions in papillary muscle). Sutureless implantation enables
minimally invasive utilization of the device, which has been
designed with a long shaft to enable use through a port access
[16]. Maximal pull force of the device on the papillary muscle
head has been tested extensively in isolated hearts and has
demonstrated similar pulling force to that of sutures
(average of 1.5 kg).
In the model used for this animal trial, the neochordal
implant released double-ended 3/0 polyester-braided
sutures with tapered needles. This allowed the implantation
of a couple of neochordae for each device. Although this
experiment was carried out with single implants, there is
potential for multiple devices to be used to address more
complex anatomies with multiple prolapsing segments. New-
generation devices are being developed with loops (single or
double) at the end of the neochordae to allow multiple
neochordal implants for each device.
The neochordal material used in the V-Chordal system has
demonstrated reliability similar to that of the conventional
PTFE in terms of durability and tissue healing (all neochords
were covered by endothelium on examination following
sacrifice). Braided sutures have been chosen because of
better durability on device fatigue-testing compared with
PTFE.
The device enabled fine tuning of the neochordal length,
following implantation, under physiologic loading conditions.
In all cases, by intention, the neochordae length was initially
kept longer than required. This was associated with a clear
demonstration of leaflet prolapse in all animals following left
atriotomy closure and weaning from cardiopulmonary
bypass. Subsequently, the neochordal length was adjusted
with sub-millimetric precision, under echocardiographic
guidance. Echocardiographic guidance has been reliable
overall; however, in a few animals, the region of the implant
showed certain Color Doppler artifacts generated by the
adjustment cable hitting the free edge. In such cases, the
neochordal length was tuned based on the correction of
coaptation height rather than on the reduction of regurgita-
tion. This limitation is expected to be addressed by second-
generation technology, which will allow disconnection of the
adjustment cable, leaving only a soft 0.01400 wire across the
valve. This wire will allow eventual re-connection of the
adjustment cable in case of need for an additional
adjustment. In addition, due to the model employed in
the present study, certain regurgitant jets unresponsive to
neochordal adjustment were observed. These jets were
usually oriented perpendicular to the coaptation area. These
jets were attributed to a consequence of the acute flail
model: in the healthy animal, the coaptation surface is
limited and leaflets are extremely thin. Following native
chordal cutting, the free edge of the leaflet tends to roll. This
tendency has been addressed by the 4/0 polypropylene staysuture; however, neochordal implantation on the free edge of
the leaflet and subsequent knot tying resulted in lack of
tissue with the reduction of the coaptation surface area
responsible for the above-mentioned jets. Such an effect is
not expected in human valves with naturally occurring
prolapse and flail because diseased segments are usually
affected by tissue. In addition, differing from such experi-
mental conditions, the clinical use of the V-Chordal device
would be expected to occur in combination with an
annuloplasty device to increase the surface area for
coaptation.
In terms of efficacy, the new device was demonstrated to
be at least as efficacious as the conventional neochordae
implant, with appropriate acute correction of MR, and stable
chronic results. Chronic implants showed normal healing of
the neochordae and the Dacron-covered spool implanted on
the papillary muscle, implying the need for the same
anticoagulant regimen as that followed for conventional
mitral repair, in clinical use.
The present experiment presents certain limitations. The
lack of a naturally occurring animal model of prolapse
necessitated the generation of an acute flail model by
chordal cutting. This resulted in a prolapse geometry solely
related to lack of primary chordae attachment, whereas in
naturally occurring prolapse, the unsupported segment is
also affected by tissue redundancy. This experiment was
conducted with single implants in each animal. In most cases,
multiple implants would be required to address valve
pathology, and studies are being conducted, at present, to
prove the feasibility of multiple implants. Further, to
eliminate any influence of adjunctive maneuvers, the
experiment also tested the isolated neochordal implant
without annuloplasty, which is not the intended use in clinical
practice. A final limitation of this study is that it utilized
epicardial echocardiography as a guiding method, because
transesophageal echocardiography is unreliable in the animal
model.
In conclusion, these authors investigated the functionality
of a device enabling a simple and reproducible technique for
the implantation and precise adjustment of neochordae. The
procedure can be safely and effectively performed; further,
it can be used in a minimally invasive environment because of
the long, flexible shaft design of the delivery system.
This study implies that intra-procedural, real-time
adjustment techniques are technically feasible and may
result in a wider application of neochordal repair, thus
enhancing chances of a successful repair and improving
potential adoption of minimally invasive approaches for the
correction of MR.
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Appendix A. Conference discussion
Dr J. Grunenfelder (Zurich, Switzerland): Well, I have to say that this is
just an ingenious invention. I think it is something which is probably going to
change our practice, and I hope so, because everybody has been struggling
with adjusting the length of the chordae and having to go back on pump to
replace the chordae. I have no doubt looking at the list of authors of this study
that this idea will take off. But I have just a few questions.
First, has the maximum pull force of this device been measured, and is it
possible to actually go onto the free wall of the left ventricle if there is no
papillary muscle? Sometimes there is just underdeveloped papillary muscle,
and I was just wondering whether you can go to the free wall and is this strong
enough to get enough force to pull the leaflet back?
And the other thing you just explained to me during the presentation. I
mean, the beating-heart left atrial approach might be difficult or dangerous
for air embolism, but you explained that in the presentation.Dr Maisano: I think the most important issue that we faced from phase 1
was the decision about whether to go for a suture-implanted device or a
sutureless-implanted device using this pigtail design. Our preclinical animal
and bench tests showed that the force of pulling the device is much higher than
is needed to keep the chords in place. The possibility of implanting this device
in a location different from the tip of the papillary muscle has not yet been
addressed, although the next generation device which we are planning to
design is one which will be implantable through a transvenous and trans-septal
approach, and we will plan to implant the device initially in the tip of the apex.
So this issue will be discussed in the future.
There is one other limitation for the application of this device in a location
different from the papillary muscle tip. In this case, if LV remodeling happens
following the procedure, there might be an inappropriate length if you implant
in a location different from the papillary muscle. In addition, the maximal
length of the device that we can design represents a constraint for implants in
a location different from the papillary muscle. At this time implant location is
not an issue, because, as you see, two sutures with needles are released. But
we are developing a new-generation device where neochordae loops will be
delivered instead of the sutures, to replicate the procedure that Professor
Mohr designed in the past.
Dr A. El-Essawi (Braunschweig, Germany): I have a technical question. If
you were doing this on a human, would you do it on the beating heart on
cardiopulmonary bypass, or after weaning from cardiopulmonary bypass,
which would be functionally more reasonable?
Dr Maisano: These questions are very important to clarify the details of
the technique. In the animal testing we decided to proceed with beating-heart
implantation because of the safety of the CPB setup in the animal. In a human
we would advise, obviously, implantation on cross-clamp under cardioplegia.
Initial adjustment can be done under cardioplegia, which is easy to do with this
automatic device. In addition, the device offers the option of leaving the
connecting cable in place, and in the event of any residual leak due to either
too long or too short chordae, the length can be adjusted afterwards.
Dr A. Calafiore (Riyadh, Saudi Arabia): Francesco, I would like just to ask
you a question. How many chords do you think you can implant with this
technique? You are limited by the tips of the papillary muscle.
Dr Maisano: This is one limitation that we already addressed. I think in
most patients probably two implants will be enough to treat the underlying
pathology. To overcome this limitation, we are designing the loop technique.
So instead of two chords coming off from the device system, we will have
multiple chords. We have already designed and implanted multiple-chord
devices, so that the next generation will be with chordal loops to implant
neochords on both leaflets from each papillary muscle.
Dr Calafiore: Just one more question. I would like to know what you think
about the problem that sometimes occurs when you unclamp the aorta and you
are off pump, the heart often is not exactly the same as the heart you will find
the day after. So adjusting the chords with a heart that often is smaller, is more
hyperactive, and the papillary muscle is closer to the other, what will happen
24 hours later? This is the question.
Dr Maisano: That is a good question. Actually we designed this device to
improve our ability to adjust the chords after implantation. Now, you are
asking me to design a device to adjust it the day after. Maybe next year we will
present the data.
Dr Calafiore: But the problem is then that you use chords that 24 hours
later will be a little bit more rested. This is my concern.
Dr Maisano: I understand your point. We occasionally see some patients
where the ventricle shrinks and it looks like the chordal length probably is too
long because of this very prominent LV remodeling, and it would be nice to have
something to go back again and readjust the length. But this is probably very
difficult to do at this time.
Dr Calafiore: Often you leave the OR with sometimes mild MR and the day
after it disappears with the neochords. Anyway, we will see.
